`
`
`
`
`
`Entered: February 2, 2018
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_______________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_______________________
`
`PAR PHARMACEUTICAL, INC.
`Petitioner
`v.
`NOVARTIS AG
`Patent Owner
`_______________________
`Case IPR2016-01059
`U.S. Patent No. 5,665,772
`_______________________
`
`
`Before LORA M. GREEN, CHRISTOPHER L. CRUMBLEY, and ROBERT A.
`POLLOCK, Administrative Patent Judges.
`
`
`PETITIONER’S REQUEST FOR REFUND OF POST-INSTITUTION FEE
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Case IPR2016-01059
`U.S. Patent No. 5,665,772
`
`
`On May 17, 2016, Par Pharmaceutical, Inc. (“Petitioner”) filed a Petition for
`
`Inter Partes Review (IPR2016-01059) seeking review of claim 7 of U.S. Patent
`
`No. 5,665,772. Pursuant to 37 C.F.R. §42.15(a)(2) and (4), Petitioner’s paid fees
`
`totaling $23,000, which included a $14,000 payment for the post-institution fee.
`
`On October 27, 2016, the Patent Trial and Appeal Board (“the Board”)
`
`denied institution of the Petition. (Paper 19). On January 11, 2018, the Board
`
`denied Petitioner’s request for rehearing (Paper 23).
`
`Therefore, because the Petition for Inter Partes review was filed after March
`
`19, 2013, and the proceeding was not instituted, Petitioner is entitled to request a
`
`refund of the post-institution fee that was previously paid. See, e.g., 78 Fed. Reg.
`
`4212, 4233 (Jan. 18, 2013), available at http://www.gpo.gov/fdsys/pkg/FR-2013-
`
`01-18/pdf/2013-00819.pdf (“The entire post-institution fee would be returned to
`
`the petitioner if the Office does not institute a review.”).
`
`Upon review and approval of the request, Petitioner respectfully asks the
`
`Board to credit $14,000 to Petitioner’s by depositing such amount into PTO
`
`Deposit Account No. 506269 of Latham & Watkins LLP.
`
`
`Date: February 2, 2018
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`By: /Daniel G. Brown/
`
`Daniel G. Brown (Reg. No. 54,005)
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`1
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Case IPR2016-01059
`U.S. Patent No. 5,665,772
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Latham & Watkins LLP
`885 Third Avenue
`New York, NY 10022-4834
`Tel: (212) 906-1200
`Fax: (212) 751-4864
`daniel.brown@lw.com
`
`
`Counsel for Petitioner
`Par Pharmaceutical, Inc.
`
`
`
`
`
`
`
`
`
`2
`
`
`
`Case IPR2016-01059
`U.S. Patent No. 5,665,772
`
`
`
`CERTIFICATE OF SERVICE
`Pursuant to 37 C.F.R. § 42.6(e), I certify that on this 2nd day of February,
`
`2018, a true and correct copy of the foregoing PETITIONER’S REQUEST FOR
`
`REFUND was served by electronic mail on Patent Owner’s lead counsel at the
`
`following email address:
`
`Nicholas N. Kallas (Reg. No. 31,530)
`Fitzpatrick, Cella, Harper & Scinto
`1290 Avenue of the Americas
`New York, NY 10104-3800
`ZortressAfinitorIPR@fchs.com
`
`
`By: / Daniel G. Brown /
`
`Daniel G. Brown (Reg. No. 54,005)
`Latham & Watkins LLP
`885 Third Avenue
`New York, NY 10022-4834
`212-906-1200; 212-751-4864 (Fax)
`
`Counsel for Petitioner
`Par Pharmaceutical, Inc.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`3
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`